Abstracts tagged "Biomarkers"

Abstract Number: 0442 • ACR Convergence 2021
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Kenichi Uto¹, Koji Ueda², Takaichi Okano¹, Kengo Akashi¹, Soshi Takahashi³, Yuji Nakamachi⁴, Takamitsu Imanishi¹, Seiji Kawano¹, Yoshihiko Yano⁵ and Jun Saegusa⁶, ¹Kobe University Hospital, Kobe, Japan, ²Japanese Foundation for Cancer Research, Tokyo, Japan, ³Shinko Hospital, Kobe, Japan, ⁴Kobe University School of Medicine, Kobe, Japan, ⁵Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, ⁶Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
Abstract Number: 0848 • ACR Convergence 2021
Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models
Zilong Yang¹, Juan Shan², Carmine Guida², Jordan Blackadar¹, Tino Cheung¹, Jeffrey Driban³, Timothy McAlindon⁴ and Ming Zhang¹, ¹Wentworth Institute of Technology, Boston, MA, ²Pace University, New York, NY, ³Tufts Medical Center, Boston, MA, ⁴Tufts Medical Center, Arlington, MA
Background/Purpose: In many hand osteoarthritis (OA) studies (e.g., automatic Joint Space Width measuring), accurate hand segmentation is the first step towards making further analysis. However,…
Abstract Number: 1206 • ACR Convergence 2021
Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Elisabeth Rasmussen¹, Liv Thiele¹, Kristian Stengaard-Pedersen², Merete Hetland³, Kim Horslev-Petersen⁴, Peter Junker⁵, Mikkel Ostergaard⁶, Aida Hansen¹, Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ⁵Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Odense M, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular synovitis and frequent occurrence of autoantibodies, playing a central role in disease progression. Anti-citrullinated peptide antibodies (ACPA)…
Abstract Number: 1384 • ACR Convergence 2021
A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis
Jennifer Franks¹, Diana Toledo¹, Viktor Martyanov¹, Yue Wang², Suiyuan Huang³, Tammara Wood¹, Cathie Spino³, Robyn Domsic⁴, Monique Hinchcliff⁵, Dinesh Khanna³ and Michael Whitfield⁶, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, West Lebanon, NH, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Yale School of Medicine, Westport, CT, ⁶Geisel School of Medicine, Lebanon, NH
Background/Purpose: Four intrinsic molecular subsets (Inflammatory, Fibroproliferative, Limited, Normal-like) have been identified in systemic sclerosis (SSc) that may have different clinical associations. To test this…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
Abstract Number: 0325 • ACR Convergence 2021
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Roberta Alexander¹, Scott Rey¹, John Conklin¹, Vinicius Domingues², Mansoor Ahmed³, Jazibeh Qureshi⁴ and Arthur Weinstein⁵, ¹Exagen Inc., Vista, CA, ²Florida State university, Daytona beach, FL, ³Arthritis Osteo Ctr of KY, Richmond, KY, ⁴Rheumatology Express, Catonsville, MD, ⁵Loma Linda University (Voluntary Position), Claremont, CA
Background/Purpose: The multianalyte assay panel (MAP) consists of cell-bound complement activation products (CB-CAPs) with lupus and non-lupus autoantibodies combined in an algorithm (Dervieux et al.,…
Abstract Number: 0449 • ACR Convergence 2021
Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
Orla Coleman¹, Bruna Wundervald², Ruoyi Zhou³, James Waddington³, Robert LJ Graham⁴, Ciaren Graham⁴, Geoff McMullan⁴, Andrew C. Parnell⁵, Vinod Chandran⁶, Philip Mease⁷, Gaia Gallo⁸, Venkatesh Krishnan⁸, Stephen Pennington⁹ and Oliver FitzGerald¹⁰, ¹Atturos, Bray, Ireland, ²Atturos, Maynooth, Ireland, ³Atturos, Belfield, Ireland, ⁴Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, ⁵Maynooth University, Maynooth, Ireland, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹University College Dublin, Dublin, Ireland, ¹⁰Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Jennifer Rogers¹, Rory Bloch², Amanda Eudy¹, David Pisetsky³, Roberta Alexander², John Conklin², Kai Sun¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²Exagen Inc., Vista, CA, ³Duke University Medical Center, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…
Abstract Number: 1207 • ACR Convergence 2021
A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Andrea Hui Ling Low¹, Fang Yi Lim² and Margaret Ma³, ¹National University of Singapore, Singapore, Singapore, ²National Univeristy of Singapore, Singapore, Singapore, ³National University Hospital, Singapore, Singapore
Background/Purpose: Serum Calprotectin level has been shown to correlate with disease activity, ultrasound (US) parameters, treatment response and clinical remission in rheumatoid arthritis (RA). The…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 1754 • ACR Convergence 2021
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Brad Rovin¹, Richard Furie², Ana Malvar³, Cynthia Aranow⁴, Jose M Pego-Reigosa⁵, Elena Zakharova⁶, Andreas Schwarting⁷, Angela Jones-Leone⁸, Anuradha Madan⁸, Jennifer Gilbride⁹, David Roth⁸, Yulia Green⁹ and André van Maurik¹⁰, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Hospital Fernandez, Buenos Aires, Argentina, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Galicia Sur Health Research Institute, Rheumatology Department and IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, Spain, ⁶Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia, ⁷University Center of Autoimmunity, Mainz, Germany, ⁸GlaxoSmithKline, Collegeville, PA, ⁹GlaxoSmithKline, Brentford, United Kingdom, ¹⁰GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a complication affecting ~40% of patients with systemic lupus erythematosus (SLE). Belimumab (BEL), an anti–B-lymphocyte stimulator therapy, was approved in…
Abstract Number: 0029 • ACR Convergence 2020
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Emma Weeding¹, Andrea Fava¹, Jill Buyon², H. Michael Belmont³, Peter Izmirly⁴, Robert Clancy⁵, Jose Monroy-Trujillo⁶, Derek Fine⁶, William Apruzzese⁷, Harald Mischak⁸ and Michelle Petri⁹, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, ⁷., Boston, ⁸Multiple Institutions, Glasgow, United Kingdom, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…
Abstract Number: 0484 • ACR Convergence 2020
Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)‑associated enzyme with paraoxonase, lactonase, and arylesterase activities. PON1 contributes to the antioxidant properties of HDL, and…
Abstract Number: 0759 • ACR Convergence 2020
Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
Yogan Kisten¹, Alexandra Circiumaru¹, Malena Loberg-Haarhaus², Nancy Vivar², Aleksandra Antovic³, Hamed Rezaei², Erik Af Klint¹, Aase Hensvold¹ and Anca Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Region, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Ultrasound (US) imaging biomarkers in the context of Anti-Citrullinated Protein Antibody (ACPA) autoimmunity might play an important role in the very early detection of…
Abstract Number: 1107 • ACR Convergence 2020
IL1RN Polymorphism Predicts Weight Loss, Inflammatory Biomarker Changes and Knee Osteoarthritis Pain Relief After Bariatric Surgery
Jonathan Samuels¹, Fernando Bomfim², Mukundan Attur³, Christine Ren-Fielding⁴, Manish Parikh⁵, Renata La Rocca-Vieira⁶ and Steven B. Abramson⁷, ¹NYU Langone, Rye Brook, NY, ²New York University, Department of Medicine, Division of Rheumatology, Millburn, NJ, ³NYU Langone Health, New York, NY, ⁴NYU Langone Health, New YOrk, ⁵Bellevue Hospital, New York, NY, ⁶NYU, New YOrk, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Symptomatic knee osteoarthritis (SKOA) patients with obesity who undergo bariatric surgery experience knee pain relief, though the reduced mechanical load explains only part of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.